NCT00331955View on ClinicalTrials.gov

Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2012

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

doxorubicin hydrochloride

Given IV

DRUG

vorinostat

Given orally

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00331955 - Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors | Biotech Hunter | Biotech Hunter